Ralph Snyderman Biography and Net Worth

Director of CareDx

Ralph Snyderman has served as a member of our board of directors since May 2005. Dr. Snyderman has held the position of chancellor emeritus and James B. Duke Professor of Medicine at Duke University since July 2004. From January 1989 to June 2004, he served as chancellor for health affairs at the Duke University School of Medicine, and was the founding CEO and president of the Duke University Health System. From January 2006 to November 2009, he consulted for New Enterprise Associates, a venture capital firm, as a venture partner. He previously served on the boards of directors of The Procter & Gamble Company, Pharmaceutical Product Development, LLC (PPD), Trevena, Inc., Crescendo Bioscience, Inc. and Targacept, Inc. He currently serves on the boards of Nodality, Inc., Press Ganey Associates, Inc., and Liquida Technologies, Inc. Dr. Snyderman is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002, the Institute of Medicine, and the American Academy of Arts & Sciences. Dr. Snyderman holds a BS in pre-medical studies from Washington College, an MD from the State University of New York, Downstate Medical Center, and completed an internship and residency in Medicine at Duke University.

What is Ralph Snyderman's net worth?: The estimated net worth of Ralph Snyderman is at least $1.36 million as of May 28th, 2021. Dr. Snyderman owns 58,549 shares of CareDx stock worth more than $1,358,922 as of November 7th. This net worth estimate does not reflect any other assets that Dr. Snyderman may own. Learn More about Ralph Snyderman's net worth.
How do I contact Ralph Snyderman?: The corporate mailing address for Dr. Snyderman and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on Ralph Snyderman's contact information.
Has Ralph Snyderman been buying or selling shares of CareDx?: Ralph Snyderman has not been actively trading shares of CareDx over the course of the past ninety days. Most recently, Ralph Snyderman sold 2,512 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $77.30, for a transaction totalling $194,177.60. Following the completion of the sale, the director now directly owns 58,549 shares of the company's stock, valued at $4,525,837.70. Learn More on Ralph Snyderman's trading history.
Who are CareDx's active insiders?: CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.
Are insiders buying or selling shares of CareDx?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 91,340 shares worth more than $3,025,415.19. The most recent insider tranaction occured on August, 21st when insider Alexander L Johnson sold 21,557 shares worth more than $702,327.06. Insiders at CareDx own 4.9% of the company. Learn More about insider trades at CareDx.
Information on this page was last updated on 8/21/2024.

Ralph Snyderman Insider Trading History at CareDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2021	Sell	2,512	$77.30	$194,177.60	58,549
5/28/2021	Sell	2,511	$81.08	$203,591.88	58,549
1/15/2021	Sell	12,000	$88.88	$1,066,560.00	72,672

Ralph Snyderman Buying and Selling Activity at CareDx

CareDx Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $23.21

$22.93

$24.85

50 Day Range

MA: $27.56

$22.13

$32.20

2 Week Range

Now: $23.21

$6.11

$34.84

Volume

980,909 shs

Average Volume

902,860 shs

Market Capitalization

$1.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.